Alcon (ALC) to acquire LumiThera
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
July 7, 2025 8:00 AM EDTLumiTheras photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD patients1,2 Nearly 200 million people globally live with dry AMD, a progressive disease with no cure, and a leading cause of blindness in developed nations3,4 Alcon aims to expand PBM office-based treatment in approved markets, underscoring its commitment to people living with retinal diseases
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in... More

